Wall Street "ACAD Meets ALL End Points, SIGNIFICANT Improvemennts" LINKED
eBay’s PayPal Payments Surge and 3 Hot Stocks Sparking Chatter
By Leah Powell | More Articles
November 27, 2012
ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) announced successful top-line results from its pivotal Phase III trial which evaluates the efficacy, tolerability, and safety of pimavanserin in patients diagnosed with Parkinson’s disease psychosis, or PDP. Pimavanserin is ACADIA’s proprietary, on-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin was successful in meeting the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale. Furthermore, Pimavanserin was successful in meeting the key secondary endpoint for motoric tolerability as measured via Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. Additionally, the results were further supported by significant improvement in the secondary efficacy measure, the Clinical Global Impression Improvement, or CGI-I, scale, and clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness, and caregiver burden. Going along with previous studies, pimavanserin was safe and well tolerated in this Phase III trial.